6-Hydroxy-CBD-C4 Anticonvulsant Activity in Treatment-Resistant Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-epileptic drugs (AEDs) are ineffective for 30% of epilepsy patients, leading to treatment-resistant epilepsy, particularly in children and young adults, who often suffer from neurological damage due to frequent seizures, necessitating the development of new therapeutic options.
Innovation Solution
The novel compound 6-hydroxy-cannabidol-C4 (6-OH-CBD-C4) is synthesized and used in pharmaceutical compositions for administration via various routes, including oral, transdermal, and nasal, to treat epilepsy, either alone or in combination with existing AEDs, through a process involving acylation, oxidation, and reduction steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-epileptic drugs are used, then most patients can control their symptoms, but 30% of patients cannot achieve seizure freedom and develop treatment-resistant epilepsy
Solution Approach 1:
The patent introduces a novel chemical compound with a modified molecular structure (6-hydroxy-cannabidol-C4) that differs from existing AEDs. This structural parameter change enables the compound to interact with different neuronal targets and pathways, potentially overcoming treatment resistance in patients who do not respond to conventional AEDs
Solution Approach 2:
The invention combines the cannabidol-C4 core structure with a hydroxyl group at the 6-position to create a composite molecular structure. This composite approach integrates the known anti-convulsant properties of cannabidol-C4 with the additional functional group, aiming to enhance or modify the pharmacological profile to treat resistant epilepsy
2Reliability
If children undergo frequent seizures, then epilepsy symptoms manifest, but neurological damage occurs causing cognitive, behavioral and motor delays
Solution Approach 1:
The patent aims to prevent neurological damage by administering the novel compound before seizures cause cumulative harm. The compound is designed to proactively stabilize neuronal excitability and prevent seizure onset, thereby protecting the developing brain from the harmful effects of repeated seizures in pediatric patients
3Measurement precision
If diagnosis investigations are undertaken for childhood epilepsy, then the cause can be identified, but diagnosis may take some time
Solution Approach 1:
The patent provides a therapeutic solution that can be implemented while diagnostic investigations are ongoing or completed. The novel compound offers immediate treatment potential without requiring extended diagnostic periods, allowing parallel pursuit of both accurate diagnosis and effective symptom management
Data Source
AI summary
The present invention relates to a compound that is pharmaceutically active and methods of preparation thereof. The compound of the invention is 6-hydroxy-cannabidol-C4 (6-OH-CBD-C4). The compound of the invention is related to cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the compound of the invention.